Best Agrolife (539660) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
23 Nov, 2025Executive summary
Q1 FY26 saw a deliberate shift to in-season sales, reducing early placements and inventory, with a focus on patented, high-margin products and operational efficiency.
Newly launched patented products, including Shot Down, Hustler, and Fetagen, performed well and received strong positive feedback from channel partners and farmers, covering over 500,000 acres.
International business expanded with new registrations and trials in Africa, Sri Lanka, Australia, and South America.
Focused on building a leaner, more sustainable business model by reducing early product placements and prioritizing in-season sales.
Financial highlights
Revenue from operations was INR 381 crore in Q1 FY26, down 27% year-over-year from INR 519 crore, but up 39% sequentially from Q4 FY25.
Gross margin improved to 30% from 24% year-over-year, with gross profit at INR 111 crore.
EBITDA was INR 46 crore (down from INR 55 crore), but EBITDA margin expanded by 125-140 bps to 12%.
Profit after tax remained stable at INR 20 crore, with cash margin rising to 5% from 4%.
EPS was INR 8.42, slightly lower than INR 9.00 in Q1 FY25.
Outlook and guidance
Revenue for FY26/27 is guided at INR 1,600-1,700 crore, with annual EBITDA margin expected to exceed 15%.
Patented products are expected to drive margin expansion and operating leverage.
Management remains confident in sustaining momentum through the Kharif season, supported by a strong product portfolio and improved margins.
Sales return target reduced to 10%-12% (from 20%-24% in prior years), supporting profitability.
Q2 expected to see revenue pickup as seasonal demand materializes.
Latest events from Best Agrolife
- Branded sales and margins surged in Q2 FY25, with strong cash flow and new patented launches ahead.539660
Q2 24/259 Jul 2026 - Q4 FY25 delivered sharp loss reduction, 103% revenue growth, and margin gains, with new launches ahead.539660
Q4 24/259 Jul 2026 - Q1 saw lower profits and revenue, but branded sales and new launches support a positive outlook.539660
Q1 24/258 Jul 2026 - Q3 FY25 revenue and profit declined amid weak demand, price pressure, and tax probe uncertainty.539660
Q3 24/258 Jul 2026 - FY26 revenue fell 31%, but margin resilience and innovation supported future outlook.539660
Q4 25/2628 May 2026 - Revenue fell 26% YoY in Q3 FY26, but margins improved and new patented products gained share.539660
Q3 25/2616 Apr 2026 - Q2 FY26 revenue dropped 30.8% YoY, but cost controls and patented products improved resilience.539660
Q2 25/2614 Nov 2025